Where Will Novo Stock Be in 10 Years?

Novo Nordisk, a Denmark-based pharmaceutical leader in diabetes and obesity markets, has faced recent setbacks but could bounce back over the next decade. The company's pipeline includes promising candidates like CagriSema, Amycretin, and UBT251 that could drive growth. However, patent expirations in 2032, increased competition, and regulatory uncertainties present significant challenges. Despite these risks, the analyst views Novo as an attractive long-term buy with potential for competitive returns, especially with dividend reinvestment.